[Autosomal dominant polycystic kidney disease: is the treatment for tomorrow?].

Abstract : Autosomal dominant polycystic kidney disease (ADPKD) is the most frequent Mendelian inherited disorder. It covers 6.1% of incident ESRD patients in France in 2011. Long left untreated, this disease will soon benefit from targeted therapies currently under evaluation. Several molecules have already reached the stage of clinical trials: the evaluation of mTOR inhibitors yielded deceiving results and, more recently, 2 different molecules demonstrated a slight impact on the progression of total kidney volume (TKV): tolvaptan, vasopressin receptor-V2 inhibitor and somatostatin analogues; both of these molecules acting throughout the decrease of intracellular AMPc. The purpose of this review is to briefly describe the signaling pathways involved, then to present both the published and ongoing clinical trials and the promising molecules evaluated in murine models.
Type de document :
Article dans une revue
Néphrologie et Thérapeutique, Elsevier Masson, 2014, 10 (6), pp.433-40
Liste complète des métadonnées

http://hal.univ-brest.fr/hal-01128884
Contributeur : Geneviève Michel <>
Soumis le : mardi 10 mars 2015 - 15:15:47
Dernière modification le : mercredi 11 mars 2015 - 01:05:55

Identifiants

  • HAL Id : hal-01128884, version 1
  • PUBMED : 25086476

Collections

Citation

Emilie Cornec-Le Gall, Yannick Le Meur. [Autosomal dominant polycystic kidney disease: is the treatment for tomorrow?].. Néphrologie et Thérapeutique, Elsevier Masson, 2014, 10 (6), pp.433-40. 〈hal-01128884〉

Partager

Métriques

Consultations de la notice

42